[Translation] An open-label, multicenter Phase I clinical study to evaluate the safety, tolerability, pharmacokinetics, and preliminary efficacy of 9MW2821 in patients with advanced solid tumors
主要研究目的:评估9MW2821 在晚期实体瘤患者中的安全性和耐受性;确定可能出现的最大耐受剂量和推荐II 期剂量。
次要研究目的:评估9MW2821 在晚期实体瘤患者中的药代动力学特征、初步疗效和免疫原性。
[Translation] Main study objectives: To evaluate the safety and tolerability of 9MW2821 in patients with advanced solid tumors; to determine the possible maximum tolerated dose and recommended phase II dose.
Secondary study objectives: To evaluate the pharmacokinetics, preliminary efficacy and immunogenicity of 9MW2821 in patients with advanced solid tumors.